Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Pentixapharm Holding AG's pretax income for the
six
months ended in Dec. 2025 was €-19.51 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2025 was €-19.51 Mil.
Pentixapharm Holding AG's pretax margin was -20,981.72%.
During the past 5 years, Pentixapharm Holding AG's highest Pretax Margin was -2512.90%. The lowest was -32392.73%. And the median was -14025.42%.
During the past 5 years, Pentixapharm Holding AG's highest Pretax Margin was -2512.90%. The lowest was -32392.73%. And the median was -14025.42%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pentixapharm Holding AG Pre-Tax Income Related Terms
Pentixapharm Holding AG Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pentixapharm Holding AG Pre-Tax Income Chart
Pentixapharm Holding AG Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Pre-Tax Income
-1.64
-2.18
-6.21
-16.55
-19.51
Pentixapharm Holding AG Semi-Annual Data
Dec21
Dec22
Dec23
Dec24
Dec25
Pre-Tax Income
-1.64
-2.18
-6.21
-16.55
-19.51
XTER:PTP vs VRTX, REGN, MRNA: Pre-Tax Income Comparison
For the Biotechnology subindustry, Pentixapharm Holding AG's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pentixapharm Holding AG Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Pentixapharm Holding AG's Pre-Tax Income falls into.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2025 was €-19.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pentixapharm Holding AG (XTER:PTP) has a Pre-Tax Income of €-19.51 Mil as of Dec. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Pentixapharm Holding AG and its competitors.
Is Pentixapharm Holding AG's Pre-Tax Income too high?
Pentixapharm Holding AG's current Pre-Tax Income is €-19.51 Mil. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Pre-Tax Income compare to VRTX and REGN?
Pentixapharm Holding AG's Pre-Tax Income of €-19.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Pentixapharm Holding AG and its competitors. Pentixapharm Holding AG's current Pre-Tax Income is €-19.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (XTER:PTP) has a current Pre-Tax Income of €-19.51 Mil. The current Pre-Tax Income is €-19.51 Mil. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Pentixapharm Holding AG (XTER:PTP), the current Pre-Tax Income is €-19.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score
Get the complete analysis for XTER:PTP
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:PTP has been successfully added to your 
